Compare RMBS & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RMBS | AXSM |
|---|---|---|
| Founded | 1990 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 8.6B |
| IPO Year | 1997 | 2015 |
| Metric | RMBS | AXSM |
|---|---|---|
| Price | $126.31 | $189.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 17 |
| Target Price | $108.17 | ★ $211.12 |
| AVG Volume (30 Days) | ★ 1.8M | 525.0K |
| Earning Date | 04-27-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 27.88 | ★ 38.56 |
| EPS | ★ 2.11 | N/A |
| Revenue | ★ $707,630,000.00 | N/A |
| Revenue This Year | $16.01 | $57.24 |
| Revenue Next Year | $16.23 | $55.88 |
| P/E Ratio | $60.08 | ★ N/A |
| Revenue Growth | ★ 27.13 | N/A |
| 52 Week Low | $43.78 | $96.09 |
| 52 Week High | $135.75 | $191.50 |
| Indicator | RMBS | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 73.28 | 72.37 |
| Support Level | $91.98 | $178.00 |
| Resistance Level | $128.23 | $191.13 |
| Average True Range (ATR) | 5.57 | 5.76 |
| MACD | 3.54 | 2.31 |
| Stochastic Oscillator | 96.01 | 95.85 |
Rambus Inc is a semiconductor company providing chips and silicon IP for data-intensive computing systems, focusing on data center and artificial intelligence (AI) infrastructure. The company is at the forefront of enabling the next era of AI-driven computing, addressing challenges of signal and power integrity at increasingly extreme data rates across the data center, edge, and client markets. It offers high-performance memory subsystems, with a balanced and diverse portfolio of products, IP, and patents that maximize performance and security in computationally intensive systems. The company operates in South Korea, Singapore, the United States, and other countries, with the majority of its revenue coming from South Korea.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.